Arca
Skip to content
Tools
Tools

-citabine

Nucleoside drugs related to cytarabine or azacitidine, used for cancer or viruses.

  • Drugs ending in -citabine: 22
  • Approved somewhere: 5
  • With a US drug page: 6

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-citabine
Class
Nucleoside drugs related to cytarabine or azacitidine, used for cancer or viruses
Most common targets
POL (5), DNA (4), Ribonucleoside-diphosphate reductase RR1 (2), DNA polymerase (alpha/delta/epsilon) (2), P (2), NS5B (2), TYMS (1), RNA (1)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -citabine, matched by spelling; those with a US drug page link to it.
Acts on
CapecitabineApprovedTYMS, DNA, RNAThymidylate synthase inhibitor
DecitabineApprovedDNMT3A, DNMT1, DNADNA (cytosine-5)-methyltransferase 3A inhibitor
EmtricitabineApprovedPOLHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
GemcitabineApprovedRibonucleoside-diphosphate reductase RR1, DNA polymerase (alpha/delta/epsilon)Ribonucleoside-diphosphate reductase RR1 inhibitor
ZalcitabineApprovedPOLHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
Emtricitabine, (+/-)-Phase 2——
ApricitabinePhase 3POL, REVERSE, TRANSCRIPTASEHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
Fosgemcitabine palabenamidePhase 3——
GuadecitabinePhase 3——
SapacitabinePhase 3DNADNA inhibitor
DexelvucitabinePhase 2POLHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
ElvucitabinePhase 2POL, PHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
IbacitabinePhase 2——
LumicitabinePhase 2LRNA-directed RNA polymerase L inhibitor
MericitabinePhase 2NS5BRNA-directed RNA polymerase inhibitor
Tezacitabine anhydrousPhase 2Ribonucleoside-diphosphate reductase RR1Ribonucleoside-diphosphate reductase RR1 inhibitor
TroxacitabinePhase 2DNA polymerase (alpha/delta/epsilon)DNA polymerase (alpha/delta/epsilon) inhibitor
ValopicitabinePhase 2NS5BRNA-directed RNA polymerase inhibitor
ValtorcitabinePhase 2DNA, PDNA inhibitor
Fostroxacitabine bralpamidePhase 1——
Gemcitabine elaidatePhase 1——
RoducitabinePhase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.